Do SGLT2i, GLP-1 RAs Cut Pneumonia, Sepsis Risk?
-
By
December 9, 2024
-
3 min
-
1
GLP-1 RAs associated with 40% reduced pneumonia risk in type 2 diabetes patients.
-
2
SGLT2i linked to a 25% reduced risk of pneumonia and severe sepsis.
-
3
Potential benefits include weight loss-mediated inflammation reduction and improved oxygen delivery to lung tissue.
-
4
Study limitations include potential residual confounding and challenges in tracking drug switching.
-
5
The need for randomized controlled trials to explore mechanisms behind associations is emphasized.
-
A large-scale study assessed the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on pneumonia and severe sepsis risks in adults with type 2 diabetes. The study found that treatment with GLP-1 RAs was associated with a 40% reduction in pneumonia risk among patients with type 2 diabetes compared to dipeptidyl peptidase-4 inhibitors (DPP-4i). Similarly, SGLT2i use was associated with a 25% reduced risk of pneumonia and severe sepsis compared to DPP-4i. The findings suggest potential benefits from these therapies in reducing pneumonia and severe sepsis risks, possibly through weight loss-mediated reduction in chronic inflammation and cardiorenal protection for GLP-1 RAs, and improved oxygen delivery to lung tissue for SGLT2i.
-
1
GLP-1 RAs associated with 40% reduced pneumonia risk in type 2 diabetes patients.
-
2
SGLT2i linked to a 25% reduced risk of pneumonia and severe sepsis.
-
3
Potential benefits include weight loss-mediated inflammation reduction and improved oxygen delivery to lung tissue.
-
4
Study limitations include potential residual confounding and challenges in tracking drug switching.
-
5
The need for randomized controlled trials to explore mechanisms behind associations is emphasized.
Listen Tab content
